Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2012

View Archived Issues

Studies assess GS-9620-induced INF-alpha response and antiviral effects

Soligenix reports thermostability of vaccines using ThermoVax

U.S. university patents new candidate vaccine adjuvants

Novel potential vaccines reported for enteroviral infections

Phase I trial studies vandetanib combination therapy for brain cancer

Scientists in Europe uncover new recognition factor for HIV-1 entry

Phase I data available on antisense drug for ALS

IntelGenx and Redhill Biopharma launch pivotal trial of antimigraine product

Epizyme forms strategic partnership with Celgene

Shire reports topline data on drug for binge eating disorder

Galenea to receive funds from the Stanley Medical Research Institute

Phase I trial tests once-daily and intermittent INK-128 dosing

Continuation recommended for trial assessing whipworm egg therapy for Crohn's disease

Mount Sinai School of Medicine evaluates IGF-1 product in autism subtype

Omthera Pharmaceuticals reports topline results from EVOLVE study

Advanced Cell Technology clear to continue Stargardt's macular dystrophy trials

GlaxoSmithKline files application in Japan for ofatumumab

Novartis extends oncology discovery research collaboration

Dynavax files BLA for hepatitis B vaccine

FDA revises Victrelis label

Jazz Pharmaceuticals enters acquisition agreement

Amgen gives update on Xgeva sBLA

Investigation at Bionature yields novel candidate oncolytics

Novel DUB/FAF-X inhibitors presented

InterMune designs novel HCV NS3/NS4A inhibitors

German university announces novel candidate analgesics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...